Canada markets close in 2 hours 24 minutes

AXSM Jan 2026 35.000 put

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
2.30000.0000 (0.00%)
As of 09:58AM EDT. Market open.
Full screen
Previous Close2.3000
Open2.3000
Bid1.8000
Ask2.9000
Strike35.00
Expire Date2026-01-16
Day's Range2.3000 - 2.3000
Contract RangeN/A
Volume1
Open Interest6
  • GlobeNewswire

    Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories

    NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system disorders, today announced that it has entered into a settlement agreement with Unichem Laboratories Ltd. (Unichem) resolving patent litigation related to Axsome’s product Sunosi® (solriamfetol). The litigation, which is pending in the United States District Court for the District of New J

  • GlobeNewswire

    Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month

    NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, announced today it is joining the migraine advocacy community to raise awareness of unmet patient needs during Migraine & Headache Awareness Month this June. “Education plays a crucial role in addressing the stigma associated with migraine, a complex neurological disorder often mis

  • GlobeNewswire

    Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month

    NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, announced today it is supporting Alzheimer’s & Brain Awareness Month this June, to help increase awareness and understanding of the challenges Alzheimer’s disease (AD) presents to patients, their caregivers, and their loved ones, and the importance of brain and mental health as cor